Related Experiment Videos
Pregnancy suppression by a structurally related antagonist for platelet activating factor, CV-6209, in mice
M Ando1, H Suginami, S Matsuura
1Department of Obstetrics and Gynecology, Ehime University School of Medicine, Japan.
Abstract:
The effects of CV-6209, a structurally related antagonist for platelet activating factor (PAF), on pregnancy were investigated in mice, so that the physiologic significance of PAF production by and secretion from preimplantation embryos could be elucidated. When it was repeatedly administered to pregnant mice during days 1-6 of pregnancy, CV-6209 prevented preimplantation thrombocytopenia and reduced the number of implantation sites dose-dependently, CV-6209 suppression of pregnancy was eliminated by concomitant administrations of PAF. When it was administered on various fractional days of pregnancy, CV-6209 suppressed pregnancy most effectively in mice treated during days 4-5 of pregnancy, the days of implantation. CV-6209 treatment exhibited no apparent effect on embryonic development. Implantation was suppressed when day 4 embryos from saline-treated donor mice were transferred in utero to CV-6209-treated recipient mice. Once implanted, however, their in utero growth was normal. The results indicate that PAF is prerequisite to pregnancy by promoting embryonic implantation.
Insights
Platelet activating factor (PAF) is crucial for successful pregnancy in mice. Blocking PAF with CV-6209 hinders embryo implantation, but this effect is reversed by administering PAF.
Area of Science:
- Reproductive biology
- Embryology
- Pharmacology
Background:
- Platelet-activating factor (PAF) is involved in various physiological processes.
- The role of PAF in early pregnancy, particularly in preimplantation embryos, requires elucidation.
Purpose of the Study:
- To investigate the physiological significance of PAF produced by preimplantation embryos.
- To determine the effects of a PAF antagonist, CV-6209, on pregnancy establishment in mice.
Main Methods:
- Administration of CV-6209, a PAF antagonist, to pregnant mice during early gestation (days 1-6).
- Dose-dependent analysis of CV-6209 effects on preimplantation thrombocytopenia and implantation site numbers.
- Evaluation of pregnancy outcomes with co-administration of PAF and CV-6209.
- Timing-specific administration of CV-6209 during critical implantation periods (days 4-5).
- Embryo transfer experiments using CV-6209-treated recipients.
Main Results:
- CV-6209 administration prevented preimplantation thrombocytopenia and reduced implantation sites dose-dependently.
- The pregnancy-suppressing effects of CV-6209 were reversed by co-administered PAF.
- CV-6209 most effectively suppressed pregnancy when administered during days 4-5, coinciding with implantation.
- Embryo implantation was inhibited in CV-6209-treated recipients, although subsequent in utero growth was normal.
- CV-6209 did not affect embryonic development.
Conclusions:
- Platelet-activating factor (PAF) is essential for successful embryo implantation in mice.
- PAF produced by embryos plays a critical role in promoting successful pregnancy establishment.
- Targeting PAF may offer therapeutic strategies for implantation disorders.